AGILeBiotics is an early-stage pharmaceutical company that is dedicated to developing innovative antibacterial solutions for patients suffering from serious lung infections with limited therapy options. As bacterial resistance continues to emerge, the use of last-resort antibiotics is becoming increasingly threatened, leaving patients in intensive care units without effective treatment. AGILeBiotics aims to address this urgent need by translating innovation into novel antibiotics.

With a specific focus on non-tuberculosis Mycobacterium (NTM) infections found in patients with Cystic Fibrosis, such as M. The company's approach involves the collaboration of regional, national, and international experts from the industry and academic institutions. By connecting diverse knowledge and expertise, AGILeBiotics is able to design and develop innovative antibiotics that combat Gram-negative bacterial resistance.

Through close collaborations with medical doctors and scientific experts, AGILeBiotics ensures a deep understanding of patients' needs and the ongoing evolution of bacterial resistance. This unique setting enables the company to find innovative solutions and facilitate the pre-clinical development of their antibiotics, ultimately aiming to improve patients' outcomes in intensive care units